Trials / Active Not Recruiting
Active Not RecruitingNCT04355689
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
Safety and Efficacy of NPI-001 Tablets Versus Placebo for Treatment of Retinitis Pigmentosa Associated With Usher Syndrome
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Nacuity Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for 24 months in subjects with vision loss due to RP associated with Usher syndrome.
Detailed description
This study will examine the safety and efficacy of oral NPI-001 Tablets as compared to oral placebo tablets for 24 months in subjects with vision loss due to RP associated with Usher syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NPI-001 | oral tablet |
| OTHER | Placebo | Placebo tablets |
Timeline
- Start date
- 2020-09-03
- Primary completion
- 2025-06-20
- Completion
- 2026-04-01
- First posted
- 2020-04-21
- Last updated
- 2025-12-23
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT04355689. Inclusion in this directory is not an endorsement.